Lorazepam in catatonia - Past, present and future of a clinical success story

The effect of lorazepam in the treatment of catatonia is outstanding and almost immediate. Clinicians are familiar with its effects: mute patients can speak again, akinetic patients can move again and patients with negativism can eat and drink again within usually a short duration of about 10 min to 1-2 h. Fear is often gone after lorazepam administration. While not always effective, the introduction of lorazepam into clinical practice represented a breakthrough and was often life-saving for many patients suffering from catatonia. It is rare to observe such rapid therapeutic effects in other domains of psychiatry. In this narrative review we will briefly look at the past, present and future of lorazepam in the treatment of catatonia. It is gratifying to reflect on the fact that clinicians using the age-old medical practice of observation and empirical treatment succeeded in advancing the management of catatonia 40 years ago. The present evidence shows that the clinical effect of lorazepam in catatonia treatment is excellent and more or less immediate although it remains to be explicitly tested against other substances such as diazepam, zolpidem, clozapine, quetiapine, amantadine, memantine, valproate and dantrolene in randomized clinical trials. In addition, future studies need to answer the question how long lorazepam should be given to patients with catatonia, months or even years? This narrative review promotes the rapid use of lorazepam in the treatment of acute catatonic patients and stipulates further scientific examination of its often impressive clinical effects.

 

Comments：

This passage discusses the history, effectiveness, and potential future directions for the use of lorazepam in the treatment of catatonia, a condition characterized by motor and behavioral disturbances. The author notes that lorazepam has been a breakthrough treatment for catatonia, with rapid and often immediate effects on patients' ability to speak, move, and eat. However, the author also suggests that further research is needed to compare lorazepam with other substances and to determine the optimal duration of treatment.

The passage highlights the importance of empirical observation and clinical practice in advancing medical treatment, and encourages clinicians to continue using lorazepam as a first-line treatment for acute catatonia. At the same time, the author acknowledges the need for rigorous scientific investigation to confirm and refine clinical observations, and to improve treatment outcomes for patients with catatonia.

Related Products

Cat.No.	Product Name	Information
S2043	Memantine HCl	Memantine HCl is an antagonist of NMDAR. It is also a CYP2B6 and CYP2D6 inhibitor for recombinant CYP2B6 and CYP2D6 with IC50 of 1.12 μM and 242.4 μM, Ki of 0.51 μM and 84.4 μM, respectively.

Related Targets

NMDAR